Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider John Fesko sold 302 shares of the stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $400.01, for a total value of $120,803.02. Following the completion of the transaction, the insider directly owned 195,276 shares of the company's stock, valued at $78,112,352.76. This represents a 0.15% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
John Fesko also recently made the following trade(s):
- On Wednesday, October 28th, John Fesko sold 898 shares of Natera stock. The stock was sold at an average price of $426.34, for a total value of $382,853.32.
- On Tuesday, October 27th, John Fesko sold 781 shares of Natera stock. The stock was sold at an average price of $406.00, for a total value of $317,086.00.
- On Monday, August 10th, John Fesko sold 6,517 shares of Natera stock. The shares were sold at an average price of $321.53, for a total value of $2,095,411.01.
Natera Trading Up 0.6%
Natera stock opened at $391.03 on Thursday. The stock has a market cap of $56.36 billion, a P/E ratio of -287.52 and a beta of 1.55. The stock has a 50 day moving average of $380.30 and a 200-day moving average of $268.64. Natera, Inc. has a 52 week low of $181.00 and a 52 week high of $437.41.
Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. The business had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The business's quarterly revenue was up 37.7% compared to the same quarter last year. During the same quarter last year, the company earned ($0.74) earnings per share. As a group, equities analysts predict that Natera, Inc. will post -1.14 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
NTRA has been the subject of several recent analyst reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Natera in a report on Thursday, October 15th. Stephens boosted their target price on shares of Natera from $305.00 to $350.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 12th. Zacks Research lowered shares of Natera from a "hold" rating to a "strong sell" rating in a research note on Friday, October 16th. Barclays increased their price target on shares of Natera from $340.00 to $475.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 7th. Finally, Guggenheim increased their price target on shares of Natera from $360.00 to $475.00 and gave the stock a "buy" rating in a research report on Thursday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, Natera currently has a consensus rating of "Moderate Buy" and a consensus price target of $394.31.
View Our Latest Stock Report on NTRA
Institutional Investors Weigh In On Natera
A number of institutional investors have recently made changes to their positions in the company. Trust Co. of Vermont acquired a new position in Natera in the second quarter worth $26,000. Elevation Wealth Partners LLC bought a new stake in Natera during the second quarter valued at $30,000. Continuum Advisory LLC bought a new stake in Natera during the second quarter valued at $33,000. Rakuten Securities Inc. bought a new stake in Natera during the second quarter valued at $35,000. Finally, Burkett Financial Services LLC acquired a new stake in shares of Natera during the third quarter worth $57,000. 99.90% of the stock is currently owned by institutional investors.
Trending Headlines about Natera
Here are the key news stories impacting Natera this week:
- Positive Sentiment: Medicare coverage for Signatera in HCC could improve patient access and support adoption of Natera’s cancer-monitoring tests. The coverage milestone adds to the commercial opportunity for its oncology business. Natera Medicare coverage for Signatera in HCC
- Positive Sentiment: New ESMO oncology evidence was described as broadening the case for Natera’s cancer-testing portfolio, potentially reinforcing the longer-term growth story. ESMO data broaden Natera’s oncology case
- Neutral Sentiment: Natera was expected to report earnings on November 5, making results and management’s outlook a near-term catalyst; the preview article did not provide reported results. Natera earnings preview
- Neutral Sentiment: The reported analyst consensus price target was $394.31, close to the share price cited in the provided market background, suggesting limited implied upside from that target alone. Natera consensus target price
- Neutral Sentiment: CFO Michael Brophy sold 1,178 shares under a pre-arranged Rule 10b5-1 plan and retained 48,480 shares. The scheduled nature and relatively small size of the sale may temper its significance as a signal about management’s outlook. CFO share sale report
Natera Company Profile
(
Get Free Report)
Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.
In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
